Medication Assisted Treatment (MAT) Training

Monday, June 3, 2019

LOCATION

University of Michigan Rachel Upjohn Building 4250 Plymouth Road Ann Arbor, MI

TIME

8:00 am - 5:00 pm

PAYMENTS FOR ATTENDANCE

The first fifteen (15)
Providers attending the full 8-hours will be paid for the day as follows:

- Physicians (MD, DO) \$500
- Advanced practice providers (NP, PA) \$250

(Available attendance payments are on first-come-first-service basis)

POST-TRAINING SUPPORT

MOC will provide aftertraining assistance to any provider needing to access a resource to answer questions or to assist with difficult cases. This support will be provided free to providers. Mi-CCSI, in partnership with the Michigan Opioid Collaborative (MOC) and the American Society of Addiction Medicine (ASAM), is hosting the ASAM Treatment of Opioid Use Disorder course. This course will provide the required eight (8) educational hours required to obtain the Medication Assisted Treatment (MAT) waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

Description

Physicians are required to complete an eight-hour training to qualify for a waiver to prescribe and dispense Buprenorphine (Drug Addiction Treatment Act of 2000). This training is certified by ASAM through which physicians are able to obtain the learning requirements necessary to obtain the waiver. This 8-hour course covers treating opioid use disorder using interactive, case-based learning and evidence-based practices. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

Learning Objectives

Upon completion of this educational activity participants should be able to:

- Summarize the clinical pharmacology, efficacy, and safety of methadone, buprenorphine, and naltrexone in treating opioid use disorders
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for initiating, stabilizing, maintaining, monitoring, and modifying treatment of patients on buprenorphine or naltrexone
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

Continuing Education Credits

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registration and more details: https://www.miccsi.org/training/mat-training/

